Feed AXGN
AX

AxoGen, Inc. AXGN · NASDAQ

$36.17 -2.53% (-$0.94)

Market cap
$1.94B
Enterprise value
$1.87B
P/E
-
Forward P/E
94.6x
PEG
-
P/S
7.7x
P/FCF
769.8x
EV/EBITDA
-
ROIC
-4.6%
Gross margin
74.6%
Net margin
-13.4%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.17
Free float
97.1%

About the company

AxoGen, Inc. (AXGN) is a biotechnology company focused on the development and manufacture of innovative therapeutic products and therapies for peripheral nerve repair. Their products are designed to aid patients with peripheral nerve damage caused by traumatic injuries or surgical procedures. AxoGen specializes in utilizing advanced technologies and biological materials to support nerve cell regeneration and restore nervous system function. The company is a leading player in the field of regenerative medicine and is focused on providing innovative solutions for the treatment of patients with nerve injuries. Shares of AxoGen, Inc. (AXGN) may be attractive to investors seeking opportunities in the biotechnology and regenerative medicine sector.

Sector

Healthcare

Industry

Medical - Devices

CEO

Michael D. Dale

Employees

622

Headquarters

Alachua

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.